...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
【24h】

Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.

机译：洛伐他汀治疗在杂合性家族性高胆固醇血症少女中的疗效和安全性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: The present study was designed to evaluate the lipid-altering efficacy, safety, and tolerability of lovastatin treatment in adolescent girls with heterozygous familial hypercholesterolemia. METHODS: A total of 54 postmenarchal girls, aged 10 to 17 years, were enrolled in a 24-week, double-blind, randomized, placebo-controlled study. After a 4-week diet/placebo run-in period, patients were randomized to 1 of 2 groups: (1) treatment with diet plus lovastatin 20 mg/day for 4 weeks, followed by diet plus lovastatin 40 mg/day for 20 weeks, or (2) diet plus placebo for 24 weeks. RESULTS: Baseline values of lipids, lipoproteins, and apolipoproteins (apo) were comparable between treatment groups. Lovastatin treatment was efficacious at reducing low-density lipoprotein cholesterol by 23% to 27%, total cholesterol by 17% to 22%, and apo B by 20% to 23% at weeks 4 and 24, respectively. Between-treatment group differences were not statistically significant for triglycerides, very-low-density lipoproteincholesterol, high-density lipoprotein cholesterol, or apo A-I. Lovastatin was generally safe and well tolerated. There were no clinically significant alterations in vital signs (blood pressure and pulse rate), anthropomorphic measurements (height, weight, and BMI), hormone levels (luteinizing hormone, follicle-stimulating hormone, dehydroepiandrosterone sulfate, estradiol, and cortisol), menstrual cycle length, or tests of liver and muscle function. CONCLUSIONS: Lovastatin offers an efficacious and well-tolerated treatment option for improving lipid profiles in adolescent girls with familial hypercholesterolemia.
机译：目的：本研究旨在评估洛伐他汀治疗杂合性家族性高胆固醇血症少女的脂质改变疗效，安全性和耐受性。方法：共有54名年龄在10至17岁的月经后女孩参加了一项为期24周，双盲，随机，安慰剂对照的研究。经过4周的饮食/安慰剂磨合期后，将患者随机分为2组中的1组：（1）饮食加洛伐他汀20 mg /天治疗4周，然后饮食加洛伐他汀40 mg /天治疗20周，或（2）饮食加安慰剂治疗24周。结果：治疗组之间脂质，脂蛋白和载脂蛋白（apo）的基线值可比。洛伐他汀治疗可在第4周和第24周有效降低低密度脂蛋白胆固醇23％至27％，总胆固醇17％至22％和apo B 20％至23％。对于甘油三酸酯，极低密度脂蛋白胆固醇，高密度脂蛋白胆固醇或载脂蛋白A-I，治疗间的差异无统计学意义。洛伐他汀一般是安全的，耐受性良好。生命体征（血压和脉搏率），拟人化测量（身高，体重和BMI），激素水平（促黄体激素，促卵泡激素，硫酸脱氢表雄酮，雌二醇和皮质醇），月经周期没有临床上的重大改变。长度或肝脏和肌肉功能的测试。结论：洛伐他汀为改善家族性高胆固醇血症青春期女孩的脂质状况提供了有效且耐受性良好的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号